KLDO

Flagship Pioneering Announces Appointment of Margo Georgiadis as CEO-Partner

Retrieved on: 
Thursday, April 7, 2022
Rubius, Therapy, Economics, Partnership, Harvard University, Medicine, CEO, Fortune, AppLovin, Technology, Mattel, Inc. v. MCA Records, Inc., McDonald's, McKinsey & Company, Education, AI, University, Macdonald, BA, Partner, Sale, Ancestry.com, Producers Guild of America Visionary Award, David Berry (inventor), Health, RO, General Catalyst, General counsel, ML, NASDAQ, Investment, Growth, Multimedia, Genomics, Chicago Innovation Awards, Intelligence, Ecosystem, Georgiadis, SANA, Discover Financial, MRNA, Company, Forbes, Organization, Leadership, Blackstone, STEM, Vaidyanathan, KLDO, Woman, Workboard, Corporate development, Flagship Pioneering, Machine learning, MBA, Regulation, Management, Pharmaceutical industry, Groupon, Residence, Flagship, Google

CAMBRIDGE, Mass., April 7, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that former Ancestry.com CEO Margo Georgiadis is joining Flagship as CEO-Partner.

Key Points: 
  • CAMBRIDGE, Mass., April 7, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that former Ancestry.com CEO Margo Georgiadis is joining Flagship as CEO-Partner.
  • said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering.
  • "I am thrilled to have the opportunity to join Flagship Pioneering and contribute to building new models for preemptive health.
  • With an unrivaled team of world-class scientists and technologists, Flagship is bringing to market transformational technology platforms that are reshaping the future of health and sustainability," said Margo Georgiadis, Flagship Pioneering CEO-Partner.

Radius Health Announces Leadership Appointments

Retrieved on: 
Wednesday, March 16, 2022
Osteoporosis, RAD1901, Prader–Willi syndrome, GLOBE, Record, KLDO, Nasdaq, Senior counsel, Fracture, Angelman syndrome, Certified Public Accountant, Spasm, Radius, Assistant, Media relations, Food, GlaxoSmithKline, Company, Man, Woman, Industry, VP, General counsel, Regulation of tobacco by the U.S. Food and Drug Administration, Marketing, Public relations, Pharmaceutical industry

BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective immediately.

Key Points: 
  • BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective immediately.
  • Mark Conley has joined Radius as the Companys Chief Financial Officer.
  • Both Kim and Mark bring significant leadership experience and technical knowledge to their roles at Radius.
  • Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology.

Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies for 2022

Retrieved on: 
Tuesday, March 8, 2022
Rubius, KLDO, David Berry (inventor), Fast Company, Plant, Climate change, Investment, World, View, Population, Doctor of Philosophy, Organization, Ecosystem, Culture, Growth, Therapy, Map, Multimedia, Flagship Pioneering, CEO, Microbiology, MRNA, Editorial, Health, SANA, RNA transfection, Carbon, NASDAQ, Agriculture, Pharmaceutical industry, Flagship

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ --Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2022, ranking as the #2 most innovative company in North America.

Key Points: 
  • CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ --Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2022, ranking as the #2 most innovative company in North America.
  • In addition to the World's 50 Most Innovative Companies, 528 organizations are recognized across 52 categories.
  • Flagship Pioneering conceives, creates, resources, and developsfirst-in-category bioplatform companies to improve human health and sustainability.
  • The World's Most Innovative Companies is Fast Company's signature franchise and one of its most highly anticipated editorial efforts of the year.

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

Retrieved on: 
Tuesday, February 15, 2022
Civic, Rubius, David Berry (inventor), SANA, Physiology, Business administration, Environmental science, Therapy, Board, Freeport, Flagship Pioneering, Monsanto, Agriculture, Hugh, Health, Chief executive officer, Farmer, KLDO, Harvard Business Review, Twitter, Sale, Food, Chief Executive (magazine), American Academy, University of Glasgow, NASDAQ, Ecosystem, MRNA, Master of Business Administration, Most, Glassdoor, PPG Industries, Board of directors, LinkedIn, Pesticide, Plant, Tree, CEO, The arts, Freeport-McMoRan, Science, Solution, Flagship, University of Edinburgh, Growth, Investment, Multimedia, Management, Medicine, Bayer

CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.
  • Hugh Grant was chairman and chief executive officer of the former Monsanto Company.
  • Grant serves as lead director of PPG Industries, Inc., and recently joined the board of Freeport McMoRan.
  • Invaio Sciences is dedicated to developing solutions that are mindful of beneficial insects, bad for pests, and safer for us all.

Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn’s and Colitis Congress

Retrieved on: 
Friday, January 21, 2022
Biomarker, Lactoferrin, Research, MMT, Inflammation, Clinical trial, Biotechnology, Private Securities Litigation Reform Act, SEC, UC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Form 10-K, Data, KLDO, Enzyme, Safety, Principle, Ulcerative colitis, GLOBE, Poster, IND, Nasdaq, Bacteria, MMTS, Pharmacology, Company, Efficiency, Food, Therapy, Colitis, SCFA, FCP, Drug discovery, Trial of the century, Pharmaceutical industry, Kaleido Star

This proof-of-principle clinical study also continues to clearly demonstrate that KB295 leads to decreases in important disease-associated biomarkers of intestinal inflammation.

Key Points: 
  • This proof-of-principle clinical study also continues to clearly demonstrate that KB295 leads to decreases in important disease-associated biomarkers of intestinal inflammation.
  • Kaleido has also been analyzing data from the full dataset, including the follow-up period, and looks forward to presenting that data at an upcoming medical meeting.
  • KB295 was evaluated in an exploratory, open-label, single arm non-IND clinical study in subjects with mild-to-moderate UC.
  • Subjects received KB295 for eight weeks, titrated up to 40g twice daily and then entered a two-week follow-up period.

Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions

Retrieved on: 
Monday, December 6, 2021
Patient, Private Securities Litigation Reform Act, MMT, Infant, Safety, Drug discovery, Company, Bacteria, IND, SEC, Therapy, Janssen, Nasdaq, Research, GLOBE, MMTS, Efficiency, Form 10-K, Food, Enzyme, Growth, KLDO, Antibiotics, Pharmaceutical industry

The collaboration is designed to explore the potential for Microbiome Metabolic Therapies (MMT) to prevent childhood-onset of atopic, immune and metabolic conditions by promoting healthy function of the gut microbiome.

Key Points: 
  • The collaboration is designed to explore the potential for Microbiome Metabolic Therapies (MMT) to prevent childhood-onset of atopic, immune and metabolic conditions by promoting healthy function of the gut microbiome.
  • Janssen will fund the additional costs associated with the expanded scope of the collaboration.
  • The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT).
  • Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.

Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation Platform

Retrieved on: 
Thursday, November 18, 2021
Biotechnology, Health, Pharmaceutical, Other Technology, Technology, Rubius, CEO, Genetic code, Peptide, Protein, Technology, Disease, Biomedicine, Health, Generate, Flagship, Labs, Biology, Therapy, Program, SANA, Nature, Cytokine, Machine learning, ADIA, Twitter, Entrepreneurship, Investor, Abu Dhabi Investment Authority, Investment, General partnership, MRNA, Abu Dhabi Investment Council, Geoffrey von Maltzahn, David Berry (inventor), Board, Â, Antibody, Epitope, Drug discovery, Flagship Pioneering, Alaska Permanent Fund, LinkedIn, Ecosystem, Drug development, Alaska, Enzyme, NASDAQ, De novo, Growth, KLDO, Fine chemical, Pharmaceutical industry, Generative Biology, Generate Biomedicines, Flagship Pioneering, GENERATIVE BIOLOGY, GENERATE BIOMEDICINES, FLAGSHIP PIONEERING

The Generate platform can rapidly generate antibodies, peptides, enzymes, cell and gene therapies to meet any therapeutic need.

Key Points: 
  • The Generate platform can rapidly generate antibodies, peptides, enzymes, cell and gene therapies to meet any therapeutic need.
  • Generate is deploying machine learning at scale to understand the genetic code underlying the function of proteins.
  • This financing will enable Generate Biomedicines to advance and evolve the platform as well as rapidly scale the organization with top-tier scientific and computational talent.
  • In addition, Generate is building two state-of-the-art facilities that will significantly expand the companys computational biology, machine learning, data generation, and wet lab capabilities.

Flagship Pioneering Announces Appointment of Justine Levin-Allerhand as Senior Partner, Corporate Development

Retrieved on: 
Monday, November 15, 2021
Rubius, Development Business, KLDO, Foundational relation, MIT, Therapy, Ecosystem, International Fundraising Consultancy, Director, Government, Engineering, Health, SANA, David Berry (inventor), Organization, Broad Institute, NASDAQ, CEO, Yale School of Medicine, Barnard College, Growth, Investment, Multimedia, Research, MRNA, Lead, Yale University, Albert Einstein College of Medicine, Broad, Corporate development, Doctor of Philosophy, Yale school, Justine, Partnership, Harvard University, Flagship Pioneering, Biology, External relations of Jersey, Rockefeller University, Management

CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Justine Levin-Allerhand, Ph.D., has joined the company in a newly created role as Senior Partner, Corporate Development.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Justine Levin-Allerhand, Ph.D., has joined the company in a newly created role as Senior Partner, Corporate Development.
  • In addition, she will advance corporate development broadly, including building new relationships with limited partners and building partnerships with aligned research and academic institutions.
  • "Justine brings to Flagship an incredible depth of experience in developing and managing not only board development and recruitment, but also how to engage and leverage boards effectively for the betterment of institutions," said Noubar Afeyan, Founder and CEO of Flagship Pioneering.
  • "I'm delighted to be joining the incredible team at Flagship Pioneering," added Justine Levin-Allerhand, Senior Partner, Corporate Development, Flagship Pioneering.

Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Retrieved on: 
Monday, November 15, 2021
KLDO, MMT, Investor, Nasdaq, Company, GLOBE, Conference, Piper Sandler Companies, Pharmaceutical industry

LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that CEO Dan Menichella will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Key Points: 
  • LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that CEO Dan Menichella will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference.
  • The presentation will be available on-demand starting at 10:00AM ET on Monday, November 22.
  • The webcast of the presentation will be made available in the Investors & Media section of Kaleidos website at https://investors.kaleido.com/events-presentations .
  • Kaleido Biosciences is a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis.

Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer

Retrieved on: 
Wednesday, November 10, 2021
Efficiency, KLDO, University, CTA, Private Securities Litigation Reform Act, Therapy, Biogen, Form 10-K, Chronic obstructive pulmonary disease, Clinical trial, Ulcerative colitis, IND, MMT, Institute, Disease, Spark Therapeutics, Food, Senior, Growth, George Mason University, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Head, Regiment University of Witwatersrand, Biotechnology, Company, GLOBE, Medicine, SEC, Nasdaq, Drug, Drug development, Pharmaceutical industry

Additionally, she will lead our medical affairs team as well as support translational microbiome research and the development of further new drug development candidates.

Key Points: 
  • Additionally, she will lead our medical affairs team as well as support translational microbiome research and the development of further new drug development candidates.
  • I am honored to be joining this talented team at Kaleido during a pivotal stage of growth for the Company, said Dr. Long.
  • She most recently served as interim Chief Medical Officer and Senior Vice President, Head of Clinical Development at Freeline Therapeutics, and was responsible for the clinical development, clinical operations, medical affairs, and regulatory functions of Freelines development programs.
  • She received her medical degree from the University of Witwatersrand, and Ph.D. in biodefense from George Mason University.